, specializes in business development, new product planning, and early brand strategy. He helps companies lay the foundation for successful launches through data-backed strategies spanning indication assessment to portfolio strategy. With a strong background in pricing and market access, Nathan integrates both commercial and access insights into early asset development to maximize market opportunity.

Articles

In part one of this four-part series regarding rare diseases, the author explores how rare disease treatment development evolved from a niche area to a cornerstone of biopharma growth. 

Rare Disease Therapies: From Niche Experiment to Strategic Growth Engine

Videos

With a potential US government shutdown looming, Megha Sinha, Kamet Consulting, discusses the impacts on pharma manufacturing and development.

How a Government Shutdown Causes FDA Inspection Bottlenecks and Backlogs

Visit PharmTech.com for upcoming coverage of the International Day of Women and Girls in Science on February 11.

Innovations from Women in STEM 

WuXi Biologics and HanchorBio partner to accelerate multi-functional fusion protein translation via end-to-end CMC and GMP services.

WuXi Biologics Collabs with HanchorBio on Next-Generation Fusion Protein Pipelines

Laine Mello, director of Marketin, Ecolab, details how AI, continuous manufacturing, and Pharma 4.0 drive bioprocessing efficiency and cost savings.

How Digitalization Is Transforming Pharmaceutical Manufacturing Processes

US WHO withdrawal triggers pharma regulatory and supply chain risks while impacting global R&D collaborations.

US Withdrawal From WHO Creates New Pharma Logistics Vulnerabilities

Raj Puri, CCO, Argonaut Manufactoring, provides key insight on navigating tariffs, supply redundancy, and the risks of compressed timelines.

Navigating the Operational Tightrope in Pharmaceutical Manufacturing

The European Commission has approved GSK’s adjuvanted recombinant respiratory syncytial virus vaccine, Arexvy, for use in adults aged 18 years and older. 

GSK’s RSV Vaccine Approved in Europe

Mirum Pharmaceuticals acquires Bluejay Therapeutics, adding a Phase 3 antibody for chronic hepatitis delta virus to its pipeline.

Mirum Acquires Bluejay, Adding Brelovitug Treatment for HDV

We're embracing who we are, magnifying engagement for scientists and innovators, personifying expertise for science-driven insights, and taking our brand and your business to the next level. Welcome to the renewed PharmTech.

News